Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts...
AACR will host the inaugural Blood Cancer Discovery Symposium March 4-6, 2024, featuring experts from all areas of blood...
January is Cervical Cancer Awareness Month. Here's the latest on prevention, screening, and treatment.
In part 2 of our 2024 Experts Forecast, Robert A. Winn, MD, FAACR, discusses ways to achieve health equity.
The blog rounds up the 2023 SABCS, which had 10,874 in-person and virtual registrants and featured cutting-edge research, thoughtful...
What experts forecast for cancer research and treatment in 2024. Part 1: Catherine J. Wu, MD, FAACR, on...
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer...
Charles Swanton, MD, PhD, FAACR, spoke on the role chromosomal instability plays in breast cancer evolution.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
“What will you do Monday morning?” was the question posed by the final session on the final full day...